TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
DocMorris ( (CH:DOCM) ) just unveiled an announcement.
DocMorris has reported a 9.5% increase in total revenue for the first nine months of 2025, driven by significant growth in both Rx and Non-Rx sales. The company has launched the AI-based DocMorris Health Companion, expanded its executive board, and is focusing on sustainable growth and profitability, with plans to achieve EBITDA breakeven by 2026. The strategic use of AI and streamlining of management structures are central to its operational efficiency and market positioning.
The most recent analyst rating on (CH:DOCM) stock is a Hold with a CHF6.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
More about DocMorris
DocMorris operates in the healthcare industry, focusing on pharmaceutical products and digital health services. The company is known for its innovative use of AI in healthcare, offering products like the DocMorris Health Companion, and has a strong market presence in Europe, particularly in Germany.
Average Trading Volume: 405,974
Technical Sentiment Signal: Sell
Current Market Cap: CHF294.1M
See more insights into DOCM stock on TipRanks’ Stock Analysis page.